Source-grounded facts extracted from Sight Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sight Sciences, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“For Against Abstain Broker Non-Votes 41,059,471 7,892 388,895 -”
Sight Sciences, Inc. shareholders approved Election of two Class II directors to serve until 2029 at the 2026-06-04 meeting.
“Name of Director For Withheld Broker Non-Votes Gerhard Burbach 24,961,185 2,877,580 13,617,493 Staffan Encrantz 23,901,624 3,937,141 13,617,493”
Sight Sciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $19.7 million, net income Net loss was $13.0 million, EPS loss of $0.24 per share. Guidance raised.
“results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026. Recent Financial and Business Highlights • Generated total revenue of $19.7 million in the first quarter of 2026, an increase of 13% compared to the same period in the prior year. • Drove Interventional Glaucoma revenue growth of 7% in the first quarter of 2026,”
Sight Sciences, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $20.4 million, net income $4.2 million, EPS $0.08 per share. Guidance initiated.
“quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026. Recent Financial Highlights • Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024. • Achieved total”
Sight Sciences, Inc. amended Second Amendment to Multi-Tenant Space Lease with Deerfield Campbell, LLC (effective 2026-01-29).
“On January 29, 2026, Sight Sciences, Inc. (the “Company”) entered into that certain Second Amendment to Multi-Tenant Space Lease (the “Second Amendment”) with Deerfield Campbell, LLC (the “Lessor”), for the Company’s headquarters located at 4040 Campbell Avenue (Suites 100 and 120), Menlo Park, California 94025.”
Sight Sciences, Inc. announced a restructuring with charges of cash restructuring charge of approximately $2.7 million to $3.0 million primarily in the third quarter of 2025, consisting mostly of one-time employee severance affecting global operations, with specific changes in the United Kingdom (reduce its headcount by 43 employees, or approximately 20% of its global workforce, including up to four UK-based employ).
“On August 27, 2025, Sight Sciences, Inc. (the “Company”) informed its employees that it is implementing a targeted plan, commencing immediately, intended to reduce operating expenses, improve cost efficiencies, and better align its operating structure for long-term, profitable growth (the “Plan”).”
Gerhard F. Burbach was appointed as Director at Sight Sciences, Inc..
“As previously disclosed, on April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.”
Gerhard F. Burbach was appointed as Director at Sight Sciences, Inc..
“On April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.”
Brenton Taylor was appointed as Executive Vice President of Operations at Sight Sciences, Inc..
“Effective as of November 4, 2024, the Board appointed Brenton Taylor as the Company’s Executive Vice President of Operations and designated him to succeed Mr. Park as the Company’s principal operating officer.”
Sam Park retired as Chief Operating Officer at Sight Sciences, Inc..
“On November 1, 2024, Sam Park, Chief Operating Officer of the Company, informed the Board of Directors of the Company (the "Board") of his decision to retire effective as of November 15, 2024.”
Sight Sciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $19.3 million. Guidance reaffirmed.
“quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year. • Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the”
Sight Sciences, Inc. reported the full year ended December 31, 2023 results: revenue $81.1 million. Guidance initiated.
“Generated full year 2023 total revenue of $81.1 million, an increase of 14% compared to full year 2022 and generated fourth quarter 2023 total revenue of $18.8 million, a decrease of 9% compared to the same period in the prior year.”
Sight Sciences, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $18.8 million. Guidance initiated.
“Revenue for the fourth quarter of 2023 was $18.8 million, a decrease of $1.8 million, or 9%, compared to the same period in the prior year.”
Sight Sciences, Inc. incurred term loan of up to $65.0 million with Hercules Capital, Inc at greater of (i) 10.35% or (ii) the Wall Street Journal prime rate plus 2.35% maturing July 1, 2028.
“Sight Sciences, Inc. (“Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc (“Hercules” or “Agent”) and certain affiliates of Hercules (collectively with Hercules, the “Lender”), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million (the “Term Loan Facility”).”
Sight Sciences, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. and certain affiliates valued at $65.0 million (effective 2024-01-22).
“On January 22, 2024 (the “Closing Date”), Sight Sciences, Inc. (“Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc (“Hercules” or “Agent”) and certain affiliates of Hercules (collectively with Hercules, the “Lender”), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million (the “Term Loan Facility”).”
Sight Sciences, Inc. amended First Amendment to Multi-Tenant Space Lease with Deerfield Campbell, LLC valued at $45,456.60 (effective 2023-12-15).
“On December 15, 2023, Sight Sciences, Inc. (the “Company”) entered into that certain First Amendment to Multi-Tenant Space Lease (the “Lease Amendment”) with Deerfield Campbell, LLC (the “Lessor”)”
Sight Sciences, Inc. reported third quarter ended September 30, 2023 results: revenue $20.0 million.
“the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023. Recent Business and Financial Highlights • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year. • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the”
Sight Sciences, Inc. announced a restructuring with charges of approximately $1.3 million (25 employees, or approximately 10% of its global workforce).
“as a result of implementing the Plan, the Company expects to record a cash restructuring charge of approximately $1.3 million in the fourth quarter of 2023, consisting primarily of one-time employee severance and benefits contribution costs”
Matthew Link was appointed as Chief Commercial Officer at Sight Sciences, Inc..
“Effective September 11, 2023, Matthew Link was appointed by the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Commercial Officer.”
Sight Sciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $23.5 million. Guidance reaffirmed.
“second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year period • Achieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye”
Sight Sciences, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 41,688,515 4,435 16,936 0”
Sight Sciences, Inc. shareholders approved Election of two Class II directors to serve until the Company's annual meeting of stockholders to be held in 2026 at the 2023-06-08 meeting.
“Item 1 – Election of two Class II directors to serve until the Company’s annual meeting of stockholders to be held in 2026 and until each such director’s respective successor has been duly elected and qualified or until each such director’s earlier death, resignation or removal. Votes FOR Votes WITHHELD Broker Non-Votes Staffan Encranz 25,200,595 10,308,666 6,200,625 Catherine Mazzacco 35,458,052 51,209 6,200,625”
Sight Sciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $18.8 million, net income $17.1 million, EPS ($0.35) per share. Guidance reaffirmed.
“results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated first quarter revenue of $18.8 million, an increase of 26% compared to the prior year period • Achieved gross margin of 84% in the first quarter of 2023 versus 80% in the first quarter of 2022 • Completed the”
Alison Bauerlein was appointed as Chief Financial Officer and Treasurer at Sight Sciences, Inc..
“Effective April 3, 2023, Alison Bauerlein was appointed by the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Financial Officer and Treasurer.”
Sight Sciences, Inc. updated its year ending December 31, 2023 guidance (initiated).
“Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the four quarter and year ended December 31, 2022 and providing guidance for the year ending December 31, 2023.”
Sight Sciences, Inc. reported the year ended December 31, 2022 results: revenue $71.3 million, net income $86.2 million, EPS $1.80 per share.
“quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023. Recent Financial Highlights • Generated 2022 total revenue of $71.3 million, an increase of 46% compared to 2021 • Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period • Reduced fourth quarter”
Sight Sciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $20.5 million, net income $16.9 million, EPS $0.35 per share.
“31, 2023. Recent Financial Highlights • Generated 2022 total revenue of $71.3 million, an increase of 46% compared to 2021 • Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period • Reduced fourth quarter 2022 operating expenses by $3.7 million versus the third quarter of 2022 • Improved total gross”
Sight Sciences, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $20.4 million to $20.6 million (Q4), $71.2 million to $71.4 million (full year).
“announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint. •”
Mack Hicks departed as Director at Sight Sciences, Inc..
“Effective January 5, 2023, Mack Hicks stepped down as a Class II director and as a member of the Audit Committee of the Board”
Jim Rodberg was appointed as Interim Chief Financial Officer and Treasurer at Sight Sciences, Inc..
“Effective January 9, 2023, Jim Rodberg, the Company’s Vice President of Finance and Corporate Controller, was appointed by the Board of Directors of the Company (the “Board”) to serve as interim Chief Financial Officer and Treasurer until the appointment of Mr. Selnick’s successor.”
Jesse Selnick departed as Chief Financial Officer and Treasurer at Sight Sciences, Inc..
“Effective January 9, 2023, Jesse Selnick, the Company’s Chief Financial Officer and Treasurer, stepped down from his positions with the Company effective immediately.”
Sight Sciences, Inc. reported full year 2022 results: revenue $70 million to $72 million. Guidance raised.
“Sight Sciences now projects revenue for the full year 2022 to range from $70 million to $72 million, which represents growth of approximately 43% to 47% compared to 2021. This compares to the prior expectation for full year 2022 revenue to range from $68 million to $72 million.”
Sight Sciences, Inc. reported third quarter ended September 30, 2022 results: revenue $18.7 million, net income $22.2 million, EPS ($0.46 per share).
“Revenue for the third quarter of 2022 was $18.7 million, an increase of $5.6 million, or 43%, compared to the third quarter of 2021. Surgical Glaucoma revenue was $17.1 million, an increase of 37% compared to the prior year period and 7% compared to the second quarter. The growth was primarily driven by an increase in both the number of facilities ordering the OMNI Surgical System and utilization per ordering facility. Dry Eye revenue was $1.6 million, an increase of 145% from the previous year and 21% from the second quarter. The growth was primarily driven by increases in sales of the Tear Care System to both new and reordering customers. Gross profit for the third quarter of 2022 was $15.7 million compared to $11.0 million for the third quarter of 2021. Gross margin for the third quarter of 2022 was 84%, in line with the same period of the prior year. Operating expenses were $37.6 million for the third quarter of 2022 compared to $25.1 million in the same period the prior year, repr”
Tamara Fountain was appointed as Director at Sight Sciences, Inc..
“On July 15, 2022, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), appointed Tamara Fountain, M.D. to the Board.”
Brenda Becker was appointed as Director at Sight Sciences, Inc..
“On March 15, 2022, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”) appointed Brenda Becker to the Board.”
Andrew Offer resigned as Class I director and Audit Committee member at Sight Sciences, Inc..
“On February 28, 2022, Andrew Offer tendered his resignation as a Class I director of the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), and stepped down from the Board and its Audit Committee, effective on March 4, 2022 (the “Effective Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.